ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 142 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 4.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,805,000 | -13.0% | 238,335 | +0.9% | 0.01% | -12.5% |
| Q1 2019 | $3,224,000 | +288.4% | 236,220 | +191.6% | 0.01% | +300.0% |
| Q4 2018 | $830,000 | -42.2% | 81,020 | -6.1% | 0.00% | -50.0% |
| Q3 2018 | $1,437,000 | +4.0% | 86,290 | -1.3% | 0.00% | 0.0% |
| Q2 2018 | $1,382,000 | +21.5% | 87,460 | -2.3% | 0.00% | +33.3% |
| Q1 2018 | $1,137,000 | +22.5% | 89,492 | +10.5% | 0.00% | 0.0% |
| Q4 2017 | $928,000 | -2.0% | 81,009 | +4.8% | 0.00% | 0.0% |
| Q3 2017 | $947,000 | +163.8% | 77,286 | +146.8% | 0.00% | +200.0% |
| Q2 2017 | $359,000 | -42.3% | 31,316 | +4.6% | 0.00% | -50.0% |
| Q1 2017 | $622,000 | -3.9% | 29,926 | -3.8% | 0.00% | 0.0% |
| Q4 2016 | $647,000 | -34.9% | 31,121 | +2.6% | 0.00% | -33.3% |
| Q3 2016 | $994,000 | +95.7% | 30,341 | +49.0% | 0.00% | +50.0% |
| Q2 2016 | $508,000 | +21.8% | 20,361 | +19.5% | 0.00% | 0.0% |
| Q1 2016 | $417,000 | – | 17,041 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
| Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
| DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
| Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
| Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
| Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
| SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
| Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
| Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
| Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |